AstraZeneca Affiliates Duck $275M Merger Payment Suit
Two AstraZeneca subsidiaries have escaped a $275M suit lodged by investors in newly acquired biopharmaceutical company Amplimmune, dodging claims that they owed stockholders milestone payments related to the development of two...To view the full article, register now.
Already a subscriber? Click here to view full article